NCT03388632: Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

NCT03388632
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 120 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Active CNS metastases
https://ClinicalTrials.gov/show/NCT03388632

Comments are closed.

Up ↑